Ascorbyl Peroxide Association With Bronchopulmonary Dysplasia
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01439295|
Recruitment Status : Completed
First Posted : September 23, 2011
Last Update Posted : November 18, 2015
|Condition or disease|
|Study Type :||Observational|
|Actual Enrollment :||51 participants|
|Official Title:||Urinary Ascorbyl Peroxide as an Early Biological Marker of Bronchopulmonary Dysplasia in Preterm Infants Less Than 33 Weeks of Gestation|
|Study Start Date :||August 2010|
|Actual Primary Completion Date :||November 2015|
|Actual Study Completion Date :||November 2015|
Preterm less than 33 weeks
This cohort will be composed of premature infants born before 33 weeks of gestational age, admitted to the neonatal intensive care unit at Sainte-Justine hospital and receiving parenteral nutrition (PN) during their first week of life.
- Bronchopulmonary Dysplasia [ Time Frame: 4 Months ]To correlate the level of urinary Ascorbyl peroxide and BPD. Full diagnosis and classification (to mild, moderate or severe) is at 36 weeks of corrected age; so even for most premature infants (like 23 weeks of gestation) there will be a need for follow up for less than 4 month to have the final diagnosis at 36 weeks
- The redox status (in blood) [ Time Frame: First week of life (week 1) and 36 semaines CA ]Testing the correlation between the urinary level of ascorbyl peroxide and the redox status in the blood at 5 to 7 days of life. Measuring the Redox potential at 36 weeks corrected age to investigate long term effect of early oxidative stress.
- Major neonatal outcomes (NEC, ROP, PDA, IVH, PVL) [ Time Frame: 4 Months ]These outcomes are the major neonatal outcomes for preterm infants, we would test the correlation between ascorbyl peroxide (as marker of oxidative stress) and like Necrotising enterocolotis (NEC), Retinopathy of prematurity (ROP),patent ductus arteriosis(PDA), intraventricular hemorrhage (IVH) and periventricular leucomalacia (PVL).
Biospecimen Retention: Samples With DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01439295
|University of Montreal, Sainte-Justine Hospital|
|Montreal, Quebec, Canada, H3T1C5|
|Principal Investigator:||Ibrahim Mohamed, Mb CHB||University of Montreal, Sainte Justine Hospital|
|Study Director:||Jean-claude Lavoie, PhD||University of Montreal, Sainte-Justine hospital research center|